

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re application of: E. DANFORTH, Jr., et al

Application No.: Continuation of 10/019,623

Filed: Herewith

For: PHARMACEUTICAL COMPOSITIONS OF TETRAC AND
METHODS OF USE THEREOF

MAIL STOP: Patent Application
Commissioner for Patents
P.O. Box 1450
Alexandria, VA 22313-1450

CERTIFICATE OF MAILING

I hereby certify that the Amendment is being deposited with U.S. Express Mail,
Express Mail label No: EV 343733077 US, in an envelope addressed to: MAIL STOP: Patent
Application, Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450

Date: 11/17/03

Elisabeth Dunkle
Elisabeth Dunkle

PRELIMINARY AMENDMENT

Please amend the application as follows:

IN THE CLAIMS:

Please cancel claims 9-15 without prejudice.

1. (Original) A pharmaceutical composition comprising tetrac, or a pharmaceutically acceptable salt thereof, admixed with a pharmaceutically acceptable carrier, which is capable of suppressing TSH secretion while reducing or avoiding the thyromimetic stimulation of peripheral tissues induced by a dose of L-thyroxine which produces an equivalent TSH-suppressive effect.

2. (Original) The pharmaceutical composition of claim 1 which further comprises an additional thyromimetic compound.

3. (Original) The pharmaceutical composition of claim 2, wherein the additional thyromimetic compound is L-thyroxine.

4. (Original) The pharmaceutical composition of claim 1 which is capable of suppressing TSH secretion while reducing or avoiding the thyromimetic stimulation of the tissues of the heart, liver, kidneys, muscle and bone as compared to the stimulation of said tissues induced by a dose of L-thyroxine which produces an equivalent TSH-suppressive effect.

5. (Original) The pharmaceutical composition of claim 1 which is capable of suppressing TSH secretion while reducing or avoiding the thyromimetic stimulation of the tissues of the heart as compared to the stimulation of said tissues induced by a dose of L-thyroxine which produces an equivalent TSH-suppressive effect.

6. (Original) The pharmaceutical composition of claim 1 which is capable of suppressing TSH secretion in a patient suffering from malignancy or other abnormal growth of the thyroid while reducing or avoiding the thyromimetic stimulation of peripheral tissues induced by a dose of L-thyroxine which produces an equivalent TSH-suppressive effect.

7. (Original) The pharmaceutical composition of claim 1 which is capable of suppressing TSH secretion without suppressing the activity of pituitary specific type II monodeiodinase.

8. (Original) The pharmaceutical composition of claim 1 which is capable of suppressing a hypothyroid condition.

16. (New). The pharmaceutical composition of claim 1 which is administered via an oral route, a nasal route, or via a parenteral route.

17 (New). The pharmaceutical composition of claim 1 wherein the pharmaceutically acceptable carrier further comprises at least any one of water, alkaline solutions, salt solutions, alcohol, vegetable oils, polyethylene glycols, gelatin, lactose, glucose, mannose, amylose, magnesium stearate, talc, silicic acid, viscous paraffin, perfume oil, fatty acid monoglycerides and diglycerides, petroethral fatty acid esters, hydroxymethyl-cellulose, polyvinylpyrrolidone, cyclodextrans, fish oils, components of fish oils, triglycerides, ω -3-fatty acids, or ω -3-fatty acid esters.

18. (New) The pharmaceutical composition of claim 1, wherein the composition can be mixed with auxiliary agents.

IN THE SPECIFICATION:

--This application is a Continuation of U.S.S.N. 10/019,623 filed May 9, 2002 which claims the benefit of PCT/US00/11166 filed April 25, 2000 which claims the benefit of 60/130,961 filed April 26, 1999.--

REMARKS


Claims 9 through 15 were cancelled without prejudice. Claims 1 through 8 are filed herewith. Claims 16 through 18 are new claims, and are numbered sequentially in the order the original claims 1-15 were filed in the parent application, U.S.S.N. 10/019,623, filed 05/09/2002.

No new matter is added by the addition of these new claims. Support for these new claims is found throughout the application, in particular page 8, lines 1 to 31 through to page 10, lines 1 to 1 to 13.

It is believed the application is in condition for immediate allowance, which action is earnestly solicited.

Respectfully submitted,

Date : November 18, 2003

A handwritten signature in dark ink, appearing to read 'D. Conlin', is written over a horizontal line.

David G. Conlin. (Reg. No. 27,026)
EDWARDS & ANGELL, LLP
P.O. Box 9169
Boston, MA 02209
Telephone: 617 439 4444